Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.

Creevey L, Bleach R, Madden SF, Toomey S, Bane FT, Varešlija D, Hill AD, Young LS, McIlroy M.

Mol Cancer Ther. 2019 Oct;18(10):1731-1743. doi: 10.1158/1535-7163.MCT-18-0791. Epub 2019 Jul 9.

PMID:
31289138
2.

S100β as a serum marker in endocrine resistant breast cancer.

Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS.

BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2.

3.

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy.

McBryan J, Fagan A, McCartan D, Bane FT, Varešlija D, Cocchiglia S, Byrne C, Bolger J, McIlroy M, Hudson L, Tibbitts P, Gaora PÓ, Hill AD, Young LS.

Clin Cancer Res. 2015 Dec 1;21(23):5371-9. doi: 10.1158/1078-0432.CCR-14-2155. Epub 2015 Aug 3.

4.

Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.

Redmond AM, Byrne C, Bane FT, Brown GD, Tibbitts P, O'Brien K, Hill AD, Carroll JS, Young LS.

Oncogene. 2015 Jul;34(29):3871-80. doi: 10.1038/onc.2014.323. Epub 2014 Oct 6.

PMID:
25284587
5.

NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis.

Qin L, Wu YL, Toneff MJ, Li D, Liao L, Gao X, Bane FT, Tien JC, Xu Y, Feng Z, Yang Z, Xu Y, Theissen SM, Li Y, Young L, Xu J.

Cancer Res. 2014 Jul 1;74(13):3477-88. doi: 10.1158/0008-5472.CAN-13-2639. Epub 2014 Apr 25.

6.

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS.

Oncogene. 2015 Jan 22;34(4):525-30. doi: 10.1038/onc.2013.586. Epub 2014 Jan 27.

PMID:
24469058
7.

Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.

Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD, Young LS.

Clin Cancer Res. 2009 Mar 15;15(6):2098-106. doi: 10.1158/1078-0432.CCR-08-1649. Epub 2009 Mar 10.

8.

The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells.

Bane FT, Bannon JH, Pennington SR, Campiani G, Williams DC, Zisterer DM, Mc Gee MM.

J Pharmacol Exp Ther. 2009 Apr;329(1):38-47. doi: 10.1124/jpet.108.148130. Epub 2009 Jan 8. Erratum in: J Pharmacol Exp Ther. 2011 Aug;338(2):729. Campaini, Giuseppe [corrected to Campiani, Giuseppe].

PMID:
19131583
9.

Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer.

Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, Hill AD, Young LS.

Oncogene. 2008 May 8;27(21):3021-31. Epub 2007 Dec 3.

PMID:
18059336

Supplemental Content

Support Center